Follow us on Facebook!
Follow us on Twitter!
Follow us on Youtube!
News archive
Recent news

 

Along with CAR-T cell treatment, bispecific antibodies has been one of the most important topics discussed at the American Society (ASH) Annual Meeting. This family of drugs has shown very promising results in early phases of clinical trials in heavily pre-treated myeloma patients. Dr Mohamad Mohty, Head of Haematology and and Celular Therapy Department, Saint-Antoine Hospital and University Pierre & Marie Curie, Paris, France, summarises for Myeloma Patients Europe (MPE) the most important updates on bispecific antibodies at ASH 2019.

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.